ClinicalTrials.gg
RecruitingNCT06567301Updated Aug 26, 2024

Extracorporeal Shockwave Versus Phonophoresis Using Chitosan-Nanoparticles Gel on Functional and Anatomical Changes Detected With Artificial Intelligence Based Texture Analysis Algorithm in Knee Osteoarthritis Patients: A Double Blind Randomized Controlled Trial

An interventional study of Ultrasound therapy combined with Chitosan nanoparticles gel in Knee Osteoarthritis, Chitosan Nanoparticles Gel and Artificial Intelligence Texture Analysis Bases Algorithm, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Cairo University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Oct 2023, registered Aug 2024).
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Osteoarthritis, Knee by Cairo University — 10 open to participants now, 12 under way, none of them phase 3. Osteoarthritis, Knee · Cairo University.

Planned enrollment
Largest of 26
120 · median 60
Started
2023
with 3 others
No phase
25 of 26
10 open now
Primary completion
2025-05
later than 5 of 11 live
Registered
18th of 26
by date

Among the 26 studies in Osteoarthritis, Knee by Cairo University, this one has the largest planned enrollment, is one of 4 that started in 2023, is one of 25 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 18th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

10 of the 26 studies in Osteoarthritis, Knee by Cairo University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteoarthritis, Knee by Cairo University, or all of them as a file.
02

Study summary

A parallel double blinded randomized controlled clinical trial (RCT) with a 1:1:1 allocation will be conducted in an orthopedic clinic in Cairo and Giza Governments - Egypt.

This RCT will evaluate the pain reduction, self-reported functional improvement, physical functional and anatomical improvement following the application of phonophoresis using chitosan-nanoparticles gel, ECSW therapy and traditional exercises compared to each other.

The treatment period will last for 4 weeks with a total of (12 sessions/ 3 sessions per week for the application of phonophoresis using chitosan-nanoparticles gel and traditional exercises program) and (5 sessions/ 1 every week for the application of ECSWT). The participants will be assessed at two different time-points (before-after treatment) with a sample size of 40 patients in each group (3 groups)

Read the detailed description

Osteoarthritis (OA) is a common degenerative disease that is ranked as the 10th largest contributor to disabilities that has a link to higher comorbidity and excess mortality. One of most common degenerative diseases is knee osteoarthritis (KOA). KOA is a progressive, chronic degenerative condition that places a heavy socioeconomic burden on healthcare systems and society. The prevalence of knee OA has sharply increased to more than the double in the last 10 years as result of steady state in life expectancy.

KOA is a well-known as a cartilage disease that involves degradation and loss of articular cartilage. However, OA is usually accompanied by changes in the subchondral bone, with sclerosis, bone cyst, and osteophyte formation.

Recent studies reported that subchondral bone remodeling plays a very important role in KOA, mediating and preceding cartilage damage. The increase in subchondral bone stiffness decreases the ability to scatter the loading forces within the knee joint, which then increases the force loaded on articular cartilage. Therefore, the cartilage damage and progress of OA accelerated over time. The focus of treatment in early KOA have shifted from the articular cartilage to the subchondral bone and become a potential therapeutic target of various therapeutic methods.

Regarding KOA pain, accumulating evidence suggests that bottom-up vascularization from subchondral bone plays a larger role than top-down vessel invasion originating from synovial tissue or synovium during cartilage erosion in OA. As a result, it is a common complaint of orthopedists that osteoarthritis pain is not associated with the radiographic presentation. Recent work revealed a relatively weak relationship between cartilage loss and OA joint pain.

As different approaches aimed at articular cartilage or synovial components had inefficient results and the mechanism of bone cartilage crosstalk is gradually becoming clear, this study will try to confirm the critical role of subchondral bone in knee osteoarthritis and that subchondral bone could be an ideal outcome measure of osteoarthritis treatment.

Low-intensity pulsed ultrasound (LIPUS) and extracorporeal shockwave therapy (ECSWT) are effective as a non-invasive method in histopathological recovery with more intense sight, ECSWT has shown effectiveness in the regression of early KOA associated with improving the subchondral bone remodeling, decrease the number of osteophytes and it can also increase osteocytes activity. Besides, ECSWT could alleviate chronic inflammatory activities in the whole joint through down-regulating inflammatory cytokines. Additionally, it was reported that application of ESWT to the subchondral bone of the knee significantly increased bone volume and trabecular number and reduced bone porosity. Overall, ESWT could reverse the pathology of OA progression to some extent.

Low-intensity US might influence the subchondral bone unit under joint disuse. LIUS with its associated acoustic radiation force can alleviate subchondral bone sclerosis during OA progression under normal joint use. In addition, if US technology combined with bioactive compounds materials as chitosan (CS), could improve the encapsulation efficiency of bioactive compounds whereas not only reduced the nanoparticle size but also narrowed their size distribution, this makes US as an effective delivery of biomaterials such as chitosan. In this context, inclusion of mixed interventions with US could improve its effect. Therefore, this study will couple the use of US therapy with a new green environmentally friendly material called chitosan in the form of a topical gel.

Chitosan appears as proteoglycan in the extracellular matrix (shells) of some species of cephalopods. Chitosan's biocompatibility, gradual degradability, non-toxicity, biological activity, anti-inflammatory properties, and antibacterial action, makes chitosan regarded as the best material for hydrogel. Some studies used CS as intra-articular injection for KOA and concluded that CS can promote chondrocyte proliferation, block inflammatory and catabolic mediators. Therefore, Phonophoresis using chitosan could reduce inflammation, limit cartilage degeneration and improve subchondral bone remodeling process.

Additionally, it is well known that confirming diagnosis of KOA is based on assessing joint space width and this is carried out through radiography which depends on the Kellgren-Lawrence grade (K-LG) scale. Despite K-LG scale is considered the most used classical diagnostic tool for KO, it has several drawbacks, including its application to the progression of diseases, its insensitivity to change, or inconsistencies in the authors' initial descriptions. Furthermore, it is limited in how it evaluates treatment efficacy because it mostly uses pain scores.

By looking to the adverse effects of conventional radiology, many studies had reported the possibility of an allergic reaction, expensive costs, lengthy inspection times, and difficulties in scanning patients with specific conditions.

Taking this into account, artificial intelligence (AI)-based approaches are starting to be used to solve these issues as image identification, pre-operative risk assessment, clinical decision- making, and analysis of large data sets, diagnosis, monitor, prognosis of rheumatological diseases, identifying risk factors for complications and has the unique ability to anticipate outcomes using patient-specific algorithms. AI plays a vital role in the appraisal of treatment, in which key progress in the clinical practice of rheumatology is the innovation of advanced imaging modalities.

The use of AI in orthopedics has mostly concentrated on the development of Machine learning (ML) and deep learning (DL) on these pictures. Deep learning, which is a subset of ML, can assist in automatic interpretation of medical images, which may increase diagnostic accuracy and speed, flag the most urgent and critical patients for immediate attention, reduce the amount of human error caused by fatigue and/or inexperience, lessen the strain on medical professionals by reducing their workload, and, in general, improve orthopedic care.

Subchondral bone-remodeling process was reported previously as an important pathophysiology of KO whereas subchondral bone sclerosis is widely considered to be the hallmark of OA. Texture analysis (TA) algorithm is used to detect changes in the subchondral bone density during remodeling process. It was demonstrated encouraging findings and the potential of automated texture analysis employing an AI algorithm as a diagnostic tool for OA in comparison to traditional TA techniques. Bone structure value (BSV) is considered as a maximum-likelihood estimator of OA as automated TA depends on it in the analysis and assessment process that measures the micro-structure of the tibial subchondral bone depends on area of interest (ROI). Consequently, the purpose of this study is to explore the difference between ECSWT, LIUS and traditional exercises regarding the pain reduction, functional improvement (self-reported and physical function) and anatomical improvement of subchondral bone (trabecular tibial bone) micro-structural changes.

03

Conditions studied

  • Knee Osteoarthritis
  • Chitosan Nanoparticles Gel
  • Artificial Intelligence Texture Analysis Bases Algorithm
  • Subchondral Bone Changes (Anatomical Changes)
  • Extracorporeal Shockwave

Keywords

  • knee osteoarthritis
  • chitosan nanoparticles gel
  • artificial intelligence
  • texture analysis
  • artificial intelligence texture analysis bases algorithm
  • chitosan
  • subchondral bone changes
  • anatomical changes
  • Extracorporeal shockwave
  • ultrasound therapy
  • Phonophoresis
  • medical imaging
  • knee OA pathogenesis
  • pathophysiology
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between ≥40 and ≤ 65 years old.
  2. Both genders.
  3. Patients should have OA of the knee, Kellgren-Lawrence scores of 2 and 3 on radiologic evaluation.
  4. If both knees diagnosed as OA, the most affected one will be selected.
  5. Diagnosis of KOA who had knee pain and functional disabilities for at least three months, according to American College of Rheumatology classification (ACR) at screening visit.
  6. Visual Analogue Scale (VAS) at rest score of ≥40 mm.
  7. Subjects have sufficient cognition that enables them to understand the requirements of the study, comply with the study procedures and visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Patients with any previous knee surgeries or lower limb fractures.
  2. Chronic inflammatory diseases such as rheumatoid arthritis.
  3. Any neurological disorders.
  4. Moderate to significant knee synovitis.
  5. Hot or red knee.
  6. History and/or physical examination findings compatible with the internal derangement of knee.
  7. Pregnancy.
  8. Patients with more than 35 (morbid obesity).
  9. Absence of current physical therapy treatments for KOA.
  10. Cognitive limitations or endocrine disease.
  11. Patients who had undergone arthroscopy or treatment with intra-articular hyaluronic acid during previous 6 months.
  12. Use of NSAIDs one week prior to screening visit.
  13. Orthopedic diseases that may affect or interfere with the therapeutic effect.
  14. Habitual use of psychotropic or narcotic analgesics for ≥1 week within 8 weeks prior to screening.
  15. Participated in other intervention studies on the past 6 months to screening
  16. Participants with congenital musculoskeletal deformity.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A: Ultrasound therapy combined with Chitosan nanoparticles gel and Exercises Program

    In this group will receive ultrasound therapy coupled with chitosan-nanoparticles gel with an exercises program. The US protocol which will consist of pulsed ultrasound waves. The parameters that will be selected consists of; frequency of 1 MHz, 1 W/cm2 power delivered at an intensity of an intensity of 2.5W/ cm2 and with duty cycle of 25% and will be applied with a 5-cm diameter applicator. The area of treatment will be cleaned to permit an effective skin applicator coupling. Each patient will be placed in a supine position for the application of ultrasound. A suitable palpation to locate the discomfort source and some passive motions to identify a range of motion restriction will be completed prior to the ultrasound application. Ultrasound will be applied to the medial and lateral aspects of the knee in circular motions, with the probe at right angles to ensure maximum absorption of energy. Each session will last for 5 minutes.

    Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel

  • Active comparator
    Group B: Application of Extracorporeal Shockwave and Exercises Program:

    This group will receive ESWT with an exercises program. Subjects will receive 5 sessions, one week apart. Before the treatment, subjects will be placed in supine to expose and prepare the treated area with the knee flexed at angle of 90° and the hip is abducted and externally rotated. The impulses will be applied on the subchondral bone at the medial and lateral tibia condyle at 2.0 cm below the joint line in anteroposterior view and 2.0 cm from the medial skin edge in lateral view. The treatment application will be as follows: 2000 impulses will be administered at (EFD) with an energy flux density ranging from 0.22-0.43 mJ / mm2 at 8 Hz. In which 0.22 mJ/mm²: likely corresponds to around 1.5-3 bars, while 0.43 mJ/mm² likely corresponds to around 3-5 bars. The probe was chosen effective treatment depth (5-20-mm focal depth), semi-movable technique of the shockwave applicator and 5 minutes duration.

    Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel

  • Placebo comparator
    Group C: Exercises Program

    Patients in this group will receive only an exercises program for 3 times weekly for 4 weeks. This program includes: (1) Warming-up (5 min); (2) strengthening exercises for the lower limbs: 3 sets of 15 repetitions: flexion SLR, abduction SLR, and extension SLR, standing knee flexion, quadriceps isometrics, 10 repetitions of 5 s, 0° and 30°; (3) aerobic exercise on a stationary bike (20 min), (4) and stretching (5 min) with a weekend break. All patients in the three groups (A, B and C) will receive the same exercise program.

    Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel

Interventions

  • Combination productUltrasound therapy combined with Chitosan nanoparticles gel

    Gymna - Belgian

    Also known as: Extracorporeal Shockwave Therapy

06

What researchers measure

Primary outcomes

  1. Anatomical improvement

    subchondral bone improvement following the application of Phonophoresis using chitosan-nanoparticles gel, ECSW therapy and assessed by Artificial intelligence based texture analysis algorithm

    Time frame: one month

Secondary outcomes

  1. level of knee pain

    by VAS

    Time frame: one month

Other outcomes

  1. Physical functional assessment

    by TUG

    Time frame: one month

  2. Self-reported functional assessment

    by the (ArWOMAC) Index for measurement of perceived health and physical function

    Time frame: one month

07

Study locations

2 of 2 sites recruiting
  • Physical Therapy College - Cairo University
    Giza, El Dokki 12613, Egypt
    Recruiting
  • Physical therapy college - Cairo University
    Giza, EL Doqqi 12613, Egypt
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2025, 19 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 19 months is close to that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 22, 2024
StartActual
Oct 25, 2023
Primary completionEst.
May 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06567301
Lead sponsor
Cairo University
Responsible party
Athar Tarek Mohamed Fahmy Azab (principle Investigators, Cairo University) — Principal investigator
First posted
Aug 22, 2024
Start date
Oct 25, 2023
Primary completion
May 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Aug 26, 2024

Study contacts

Athar Tarek Mohamed Fahmy Azab, Master
Contact
athartarek29790@gmail.com
0201001909236
Hamdy Mamdouh Amir
Contact
athartarek29790@gmail.com
0201112831021
Athar Tarek Mohamed Fahmy Azab
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion